Genscript Biotech (HKSE:01548) EBIT per Share : HK$-1.20 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech EBIT per Share?

Genscript Biotech's EBIT per Share for the six months ended in Dec. 2023 was HK$-0.34. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.20.

During the past 3 years, the average EBIT per Share Growth Rate was -23.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Genscript Biotech's EBIT per Share or its related term are showing as below:

HKSE:01548' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.2 Med: -21.75 Max: 70.4
Current: -23.6

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Genscript Biotech was 70.40% per year. The lowest was -45.20% per year. And the median was -21.75% per year.

HKSE:01548's 3-Year EBIT Growth Rate is ranked worse than
77.24% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs HKSE:01548: -23.60

Genscript Biotech's EBIT for the six months ended in Dec. 2023 was HK$-713 Mil.

Genscript Biotech EBIT per Share Historical Data

The historical data trend for Genscript Biotech's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech EBIT per Share Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.48

-1.14

-1.98

-1.55

-1.20

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial														-1.37	-0.85	-0.71	-0.86	-0.34

Genscript Biotech EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Genscript Biotech's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2526.228	/	2109.365
=	-1.20

Genscript Biotech's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-712.871	/	2111.849
=	-0.34

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.20

Genscript Biotech (HKSE:01548) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Genscript Biotech EBIT per Share Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Executives

Wang Luquan	2401 A concert party to an agreement to buy shares
Wang Ye	2101 Beneficial owner
Zhang Fangliang	2401 A concert party to an agreement to buy shares
Huang Lili	2202 Interest of your spouse
Hu Zhiyong	2201 Interest of corporation controlled by you
Jin Weihong	2201 Interest of corporation controlled by you
Genscript Corporation	2101 Beneficial owner
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Gns Holdings Limited	2101 Beneficial owner
Hillhouse Capital Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines